We identified a previously unknown downstream target of β-catenin, HAS2, in prostate cancer, and found that high β-catenin nuclear localization and low or no AR expression may define a subpopulation of men with bone metastatic prostate cancer.
These findings may guide physicians in managing these patients.
2012-02-02
Eng.
Clinical cancer research : an official journal of the American Association for Cancer Research
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Clin Cancer Res. 2012 Feb;18(3):726-36
© Galenicom 1999-2013